Antithrombin improves fetal condition in women with severe pre-eclampsia before 32 weeks of gestation; a randomized, double-blind, placebo-controlled trial
- PMID: 18226126
- DOI: 10.1111/j.1447-0756.2007.00677.x
Antithrombin improves fetal condition in women with severe pre-eclampsia before 32 weeks of gestation; a randomized, double-blind, placebo-controlled trial
Abstract
Aim: To see if antithrombin (AT) supplementation improved fetal outcomes in early onset (<32 weeks) severe pre-eclampsia.
Methods: A subgroup re-analysis of an original randomized controlled trial of AT in pre-eclampsia between 24 and 35 weeks of gestation was performed. Either AT (3000 IU/day, n=42) or placebo (Albumin 582 mg/day, n=42) were administered for 7 days. Fetal weight gain, biophysical profile score and fetal heart rate monitoring were evaluated during the treatment week and until delivery. Comparisons were performed by intent-to-treat and relative risk (RR) and 95% Confidence Intervals (CI) were obtained.
Results: In each group, 27 women (64%) completed the allocated intervention. AT significantly decreased the worsening of the fetal biophysical profile score or fetal heart rate monitoring (RR 0.24, 95% CI 0.07-0.8), increased the incidence of estimated weight gain >15 g/day during the intervention week (3.1, 1.0-9.9), and prolonged gestational age to >or= 34 weeks (3.6, 1.05-12.6), however infant mortality rates did not differ between the two groups. No adverse events related to AT were observed.
Conclusions: Supplementation of AT preserves fetal biophysical condition and weight gain in early onset severe pre-eclampsia and most likely prolongs pregnancies >or= 34 weeks of gestation.
Similar articles
-
Antithrombin therapy for severe preeclampsia: results of a double-blind, randomized, placebo-controlled trial. BI51.017 Study Group.Thromb Haemost. 2000 Oct;84(4):583-90. Thromb Haemost. 2000. PMID: 11057854 Clinical Trial.
-
World Health Organisation multicentre randomised trial of supplementation with vitamins C and E among pregnant women at high risk for pre-eclampsia in populations of low nutritional status from developing countries.BJOG. 2009 May;116(6):780-8. doi: 10.1111/j.1471-0528.2009.02158.x. BJOG. 2009. PMID: 19432566 Clinical Trial.
-
Treatment of severe preeclampsia with antithrombin concentrate: results of a prospective feasibility study.Semin Thromb Hemost. 2003 Dec;29(6):645-52. doi: 10.1055/s-2004-815632. Semin Thromb Hemost. 2003. PMID: 14719181 Clinical Trial.
-
Effect of supplementation of women in high-risk pregnancies with long-chain polyunsaturated fatty acids on pregnancy outcomes and growth measures at birth: a meta-analysis of randomized controlled trials.Br J Nutr. 2007 Aug;98(2):253-9. doi: 10.1017/S0007114507709078. Epub 2007 Apr 10. Br J Nutr. 2007. PMID: 17419889 Review.
-
Adverse pregnancy outcome, the uteroplacental interface, and preventive strategies.Semin Perinatol. 2007 Aug;31(4):208-12. doi: 10.1053/j.semperi.2007.05.002. Semin Perinatol. 2007. PMID: 17825674 Review.
Cited by
-
Preeclampsia: Risk Factors, Diagnosis, Management, and the Cardiovascular Impact on the Offspring.J Clin Med. 2019 Oct 4;8(10):1625. doi: 10.3390/jcm8101625. J Clin Med. 2019. PMID: 31590294 Free PMC article. Review.
-
Potential biological therapies for severe preeclampsia: a systematic review and meta-analysis.BMC Pregnancy Childbirth. 2019 May 9;19(1):163. doi: 10.1186/s12884-019-2268-9. BMC Pregnancy Childbirth. 2019. PMID: 31072315 Free PMC article.
-
Antithrombin III for critically ill patients.Cochrane Database Syst Rev. 2016 Feb 8;2(2):CD005370. doi: 10.1002/14651858.CD005370.pub3. Cochrane Database Syst Rev. 2016. PMID: 26858174 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
